← Leaderboards
Steffen Mueller
Codagenix, Inc.
$7,040,356
Attributed
$7,040,356
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2014–22$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,040,356 · 4
By mechanism
R44$6,417,850 · 2
R43$622,506 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesAttenuatedVirusDesignVaccinesBaseImmune ResponseViralTechnologyEngineeringVaccine CandidateAnimal ModelHuman PoliovirusAnimalsMutationInfluenzaGeneticDosePreclinical TestingImmunogenicityLifeComputer AssistedAge-YearsAttenuated Vaccines
Grant awards (10)
A rationally-designed, live-attenuated RSV vaccine for the elderly$809,351
R44 · FY2022 · AI · contact PI
Final Preclinical Testing and Formulation of a Scalable, Live-attenuated SARS-CoV-2 Vaccine$999,267
R44 · FY2021 · AI · contact PI
A rationally-designed, live-attenuated RSV vaccine for the elderly$665,459
R44 · FY2021 · AI · contact PI
Rapid generation and testing of live-attenuated vaccines against SARS-CoV-2$1,716,496
R44 · FY2020 · AI · contact PI
A rationally-designed, live-attenuated RSV vaccine for the elderly$727,278
R44 · FY2020 · AI · contact PI
Pre-clinical Commercialization of a Synthetically Designed, Live-attenuated RSV Vaccine$744,622
R44 · FY2018 · AI · contact PI
Pre-clinical Commercialization of a Synthetically Designed, Live-attenuated RSV Vaccine$755,377
R44 · FY2017 · AI · contact PI
Balancing Immunogenicity of a Tetravalent Live Attenuated Dengue Vaccine$222,698
R43 · FY2015 · AI · contact PI
Ultra-low dose Influenza vaccines$199,904
R43 · FY2015 · AI · contact PI
Ultra-low dose Influenza vaccines$199,904
R43 · FY2014 · AI · contact PI